| |
Record |
Warning: mysql_fetch_field() expects parameter 2 to be long, string given in /home/arimmora/public_html/refbase/includes/include.inc.php on line 309
Links |
|
Author  |
Barbault, A.; Costa, F.P.; Bottger, B.; Munden, R.F.; Bomholt, F.; Kuster, N.; Pasche, B. |
|
| |
Title |
Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach |
Type |
Journal Article |
| |
Year |
2009 |
Publication |
Journal of Experimental & Clinical Cancer Research : CR |
Abbreviated Journal |
J Exp Clin Cancer Res |
|
| |
Volume |
28 |
Issue |
|
Pages |
51 |
|
| |
Keywords |
Adult; Aged; Aged, 80 and over; Biopsy; *Electromagnetic Fields; Female; Humans; *Magnetic Field Therapy/adverse effects; Male; Middle Aged; Neoplasms/blood/diagnosis/surgery/*therapy; Positron-Emission Tomography; Tomography, X-Ray Computed; Tumor Markers, Biological/blood |
|
| |
Abstract |
PURPOSE: Because in vitro studies suggest that low levels of electromagnetic fields may modify cancer cell growth, we hypothesized that systemic delivery of a combination of tumor-specific frequencies may have a therapeutic effect. We undertook this study to identify tumor-specific frequencies and test the feasibility of administering such frequencies to patients with advanced cancer. PATIENTS AND METHODS: We examined patients with various types of cancer using a noninvasive biofeedback method to identify tumor-specific frequencies. We offered compassionate treatment to some patients with advanced cancer and limited therapeutic options. RESULTS: We examined a total of 163 patients with a diagnosis of cancer and identified a total of 1524 frequencies ranging from 0.1 Hz to 114 kHz. Most frequencies (57-92%) were specific for a single tumor type. Compassionate treatment with tumor-specific frequencies was offered to 28 patients. Three patients experienced grade 1 fatigue during or immediately after treatment. There were no NCI grade 2, 3 or 4 toxicities. Thirteen patients were evaluable for response. One patient with hormone-refractory breast cancer metastatic to the adrenal gland and bones had a complete response lasting 11 months. One patient with hormone-refractory breast cancer metastatic to liver and bones had a partial response lasting 13.5 months. Four patients had stable disease lasting for +34.1 months (thyroid cancer metastatic to lung), 5.1 months (non-small cell lung cancer), 4.1 months (pancreatic cancer metastatic to liver) and 4.0 months (leiomyosarcoma metastatic to liver). CONCLUSION: Cancer-related frequencies appear to be tumor-specific and treatment with tumor-specific frequencies is feasible, well tolerated and may have biological efficacy in patients with advanced cancer. TRIAL REGISTRATION: clinicaltrials.gov identifier NCT00805337. |
|
| |
Address |
Cabinet Medical, Avenue de la Gare 6, Lausanne, Switzerland. alexandre.barbault@gmail.com |
|
| |
Corporate Author |
|
Thesis |
|
|
| |
Publisher |
|
Place of Publication |
|
Editor |
|
|
| |
Language |
English |
Summary Language |
|
Original Title |
|
|
| |
Series Editor |
|
Series Title |
|
Abbreviated Series Title |
|
|
| |
Series Volume |
|
Series Issue |
|
Edition |
|
|
| |
ISSN |
0392-9078 |
ISBN |
|
Medium |
|
|
| |
Area |
|
Expedition |
|
Conference |
|
|
| |
Notes |
PMID:19366446 |
Approved |
no |
|
| |
Call Number |
IT'IS @ evaj @ |
Serial |
281 |
|
| Permanent link to this record |
